BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24566592)

  • 1. Canadian health care institution resource utilization resulting from skeletal-related events.
    Habib MJ; Merali T; Mills A; Uon V
    Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
    Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
    J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
    Hagiwara M; Delea TE; Chung K
    J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of skeletal complications from bone metastases in six European countries.
    Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
    J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
    Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
    J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
    Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
    Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
    Barlev A; Song X; Ivanov B; Setty V; Chung K
    J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.
    Carter JA; Ji X; Botteman MF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):483-96. PubMed ID: 23862654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
    Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
    Hagiwara M; Delea TE; Saville MW; Chung K
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of treating skeletal-related events in patients with prostate cancer.
    Lage MJ; Barber BL; Harrison DJ; Jun S
    Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health resource utilization associated with skeletal-related events: results from a retrospective European study.
    Body JJ; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
    Eur J Health Econ; 2016 Jul; 17(6):711-21. PubMed ID: 26253584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
    Yong C; Onukwugha E; Mullins CD
    Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
    Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
    J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
    Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
    McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
    Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.